For the REACT study, which was published recently in Clinical Infectious Diseases, it was a multicenter international study testing in the ELISPOT assay for CMV, which is an interferon gamma release assay with the ELISPOT platform, trying to see if this new test can predict CMV reactivation after allogenic STEM cell transplantation.
And what we found that this was really an independent predictor of protection against the CMV reactivation, if you have enough solar mediated immunity for CMV that you can identify by the ELISPOT assay...
For the REACT study, which was published recently in Clinical Infectious Diseases, it was a multicenter international study testing in the ELISPOT assay for CMV, which is an interferon gamma release assay with the ELISPOT platform, trying to see if this new test can predict CMV reactivation after allogenic STEM cell transplantation.
And what we found that this was really an independent predictor of protection against the CMV reactivation, if you have enough solar mediated immunity for CMV that you can identify by the ELISPOT assay. So, it was a positive study, but at the same time, what we saw in a subgroup analysis that patient will have low cellular mediated immunity and had a CMV reactivation, they had the worst outcome. It [inaudible] in mortality compared to patients who had good CMV cellular immunity and no CMV reactivation for example.
